No Data
No Data
Leerink Partners Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $5
Leerink Partners Remains a Buy on AbCellera Biologics (ABCL)
Express News | Abcellera Biologics Inc : Leerink Partners Cuts Target Price to $5 From $7
KeyBanc Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $5
Keybanc Maintains Overweight on AbCellera Biologics, Raises Price Target to $5
Institutions Profited After AbCellera Biologics Inc.'s (NASDAQ:ABCL) Market Cap Rose US$92m Last Week but Individual Investors Profited the Most